The FDA on August 15, 2024, approved IMFINZI® with Platinum-containing chemotherapy as neoadjuvant treatment, followed by single-agent IMFINZI® as adjuvant treatment after surgery for adults with resectable (tumors ≥ 4 cm and/or node positive) Non-Small Cell Lung Cancer (NSCLC) and no known Epidermal Growth Factor Receptor (EGFR) mutations or Anaplastic Lymphoma Kinase (ALK) rearrangements. IMFINZI® is a product of AstraZeneca.
Bottom Ad
Advertisement
Subscribe
